US2011129459A1PendingUtilityA1

Anti-nr10 antibody and use thereof

66
Assignee: CHUGAI PHARMACEUTICAL CO LTDPriority: Dec 5, 2007Filed: Dec 5, 2008Published: Jun 2, 2011
Est. expiryDec 5, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Taichi KuramochiKeiko KasutaniSouhei OhyamaHiroyuki TsunodaTomoyuki IgawaTatsuhiko TachibanaHirotake ShiraiwaKeiko Esaki
A61P 37/00A61P 29/00A61K 2039/505C07K 2317/567C07K 2317/565C07K 2317/56A61K 39/395G01N 33/6869G01N 2333/7155C07K 2317/92C07K 2317/76C07K 2317/24C07K 16/2866
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.

Claims

exact text as granted — not AI-modified
1 . An antibody that recognizes domain 1 of NR10. 
     
     
         2 . The antibody of  claim 1 , which has a neutralizing activity. 
     
     
         3 . The antibody of  claim 1 , which is a humanized antibody. 
     
     
         4 . An anti-NR10 antibody which is any one of:
 (1) an antibody comprising a heavy chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 1, CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and CDR3 comprising the amino acid sequence of SEQ ID NO: 3;   (2) an antibody comprising the heavy chain variable region of SEQ ID NO: 4;   (3) an antibody comprising a light chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 5, CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and CDR3 comprising the amino acid sequence of SEQ ID NO: 7;   (4) an antibody comprising the light chain variable region of SEQ ID NO: 8;   (5) an antibody comprising the heavy chain variable region of (1) and the light chain variable region of (3);   (6) an antibody comprising the heavy chain variable region of (2) and the light chain variable region of (4);   (7) an antibody comprising a heavy chain variable region at least 95% identical to SEQ ID NO: 4 and a light chain variable region at least 95% identical to SEQ ID NO: 8; and   (8) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (1) to (7).   
     
     
         5 . An anti-NR10 antibody which is any one of:
 (1) an antibody comprising a heavy chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 9, CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and CDR3 comprising the amino acid sequence of SEQ ID NO: 11;   (2) an antibody comprising the heavy chain variable region of SEQ ID NO: 12;   (3) an antibody comprising a light chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 13, CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and CDR3 comprising the amino acid sequence of SEQ ID NO: 15;   (4) an antibody comprising the light chain variable region of SEQ ID NO: 16;   (5) an antibody comprising the heavy chain variable region of (1) and the light chain variable region of (3);   (6) an antibody comprising the heavy chain variable region of (2) and the light chain variable region of (4);   (7) an antibody comprising a heavy chain variable region at least 95% identical to SEQ ID NO: 12 and a light chain variable region at least 95% identical to SEQ ID NO: 16; and   (8) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (1) to (7).   
     
     
         6 . An anti-NR10 antibody which is any one of:
 (1) an antibody comprising a heavy chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 17, CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and CDR3 comprising the amino acid sequence of SEQ ID NO: 19;   (2) an antibody comprising the heavy chain variable region of SEQ ID NO: 20;   (3) an antibody comprising a light chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 21, CDR2 comprising the amino acid sequence of SEQ ID NO: 22, and CDR3 comprising the amino acid sequence of SEQ ID NO: 23;   (4) an antibody comprising the light chain variable region of SEQ ID NO: 24;   (5) an antibody comprising the heavy chain variable region of (1) and the light chain variable region of (3);   (6) an antibody comprising the heavy chain variable region of (2) and the light chain variable region of (4);   (7) an antibody comprising a heavy chain variable region at least 95% identical to SEQ ID NO: 20 and a light chain variable region at least 95% identical to SEQ ID NO: 24; and   (8) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (1) to (7).   
     
     
         7 . An anti-NR10 antibody which is any one of:
 (1) an antibody comprising a heavy chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 25, CDR2 comprising the amino acid sequence of SEQ ID NO: 26, and CDR3 comprising the amino acid sequence of SEQ ID NO: 27;   (2) an antibody comprising the heavy chain variable region of SEQ ID NO: 28;   (3) an antibody comprising a light chain variable region which comprises CDR1 comprising the amino acid sequence of SEQ ID NO: 29, CDR2 comprising the amino acid sequence of SEQ ID NO: 30, and CDR3 comprising the amino acid sequence of SEQ ID NO: 31;   (4) an antibody comprising the light chain variable region of SEQ ID NO: 32;   (5) an antibody comprising the heavy chain variable region of (1) and the light chain variable region of (3);   (6) an antibody comprising the heavy chain variable region of (2) and the light chain variable region of (4);   (7) an antibody comprising a heavy chain variable region at least 95% identical to SEQ ID NO: 28 and a light chain variable region at least 95% identical to SEQ ID NO: 32; and   (8) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (1) to (7).   
     
     
         8 . An antibody or antibody variable region which is any one of:
 (1) a heavy chain variable region comprising CDR1 of SEQ ID NO: 196, CDR2 of SEQ ID NO: 197, and CDR3 of SEQ ID NO: 11 (H17);   (2) a heavy chain variable region comprising CDR1 of SEQ ID NO: 176, CDR2 of SEQ ID NO: 197, and CDR3 of SEQ ID NO: 11 (H19);   (3) a heavy chain variable region comprising CDR1 of SEQ ID NO: 196, CDR2 of SEQ ID NO: 197, and CDR3 of SEQ ID NO: 184 (H28, H42);   (4) a heavy chain variable region comprising CDR1 of SEQ ID NO: 9, CDR2 of SEQ ID NO: 197, and CDR3 of SEQ ID NO: 184 (H30, H44);   (5) a heavy chain variable region comprising CDR1 of SEQ ID NO: 176, CDR2 of SEQ ID NO: 197, CDR3 of SEQ ID NO: 184 (H34, H46);   (6) a heavy chain variable region comprising CDR1 of SEQ ID NO: 9, CDR2 of SEQ ID NO: 198, and CDR3 of SEQ ID NO: 184 (H57, 1178);   (7) a heavy chain variable region comprising CDR1 of SEQ ID NO: 176, CDR2 of SEQ ID NO: 198, and CDR3 of SEQ ID NO: 184 (H71, H92);   (8) a heavy chain variable region comprising CDR1 of SEQ ID NO: 9, CDR2 of SEQ ID NO: 199, and CDR3 of SEQ ID NO: 184 (H97, H98);   (9) a light chain variable region comprising CDR1 of SEQ ID NO: 200, CDR2 of SEQ ID NO: 170, and CDR3 of SEQ ID NO: 193 (L11);   (10) a light chain variable region comprising CDR1 of SEQ ID NO: 201, CDR2 of SEQ ID NO: 170, and CDR3 of SEQ ID NO: 193 (L12);   (11) a light chain variable region comprising CDR1 of SEQ ID NO: 202, CDR2 of SEQ ID NO: 170, and CDR3 of SEQ ID NO: 193 (L17);   (12) a light chain variable region comprising CDR1 of SEQ ID NO: 203, CDR2 of SEQ ID NO: 170, and CDR3 of SEQ ID NO: 193 (L50);   (13) an antibody comprising the heavy chain variable region of (3) and the light chain variable region of (11);   (14) an antibody comprising the heavy chain variable region of (4) and the light chain variable region of (11);   (15) an antibody comprising the heavy chain variable region of (5) and the light chain variable region of (11);   (16) an antibody comprising the heavy chain variable region of (6) and the light chain variable region of (11);   (17) an antibody comprising the heavy chain variable region of (7) and the light chain variable region of (11);   (18) an antibody comprising the heavy chain variable region of (8) and the light chain variable region of (12);   (19) an antibody comprising a heavy chain variable region at least 95% identical and a light chain variable region at least 95% identical to the heavy and light chain variable regions of the antibody of any one of (13) to (18); and   (20) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (13) to (18).   
     
     
         9 . An antibody or antibody variable region which is any one of:
 (1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 204 (H17);   (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 205 (H19);   (3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 206 (H28);   (4) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 207 (H30);   (5) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 208 (H34),   (6) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 209 (H42);   (7) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 210 (H44);   (8) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 211 (H46);   (9) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 212 (H57);   (10) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 213 (H71);   (11) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 214 (H78);   (12) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 215 (H92);   (13) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 216 (H97);   (14) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 217 (H98);   (15) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 218 (L11);   (16) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 219 (L12);   (17) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220 (L17);   (18) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 221 (L50);   (19) an antibody comprising the heavy chain variable region of (3) and the light chain variable region of (17) (H28L17);   (20) an antibody comprising the heavy chain variable region of (4) and the light chain variable region of (17) (H30L17);   (21) an antibody comprising the heavy chain variable region of (5) and the light chain variable region of (17) (H34L17);   (22) an antibody comprising the heavy chain variable region of (6) and the light chain variable region of (17) (H42L17);   (23) an antibody comprising the heavy chain variable region of (7) and the light chain variable region of (17) (H44L17);   (24) an antibody comprising the heavy chain variable region of (8) and the light chain variable region of (17) (H46L17);   (25) an antibody comprising the heavy chain variable region of (9) and the light chain variable region of (17) (H57L17);   (26) an antibody comprising the heavy chain variable region of (10) and the light chain variable region of (17) (H71L17);   (27) an antibody comprising the heavy chain variable region of (11) and the light chain variable region of (17) (H78L17);   (28) an antibody comprising the heavy chain variable region of (12) and the light chain variable region of (17) (H92L17);   (29) an antibody comprising the heavy chain variable region of (13) and the light chain variable region of (18) (H97L50);   (30) an antibody comprising the heavy chain variable region of (14) and the light chain variable region of (18) (H98L50),   (31) an antibody comprising a heavy chain variable region at least 95% identical and a light chain variable region at least 95% identical to the heavy and light chain variable regions of the antibody of any one of (19) to (30); and   (32) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (19) to (30).   
     
     
         10 . The anti-NR10 antibody of  claim 4 , which is a humanized antibody. 
     
     
         11 . An antibody, antibody heavy chain, or antibody light chain, which is any one of:
 (1) a heavy chain comprising the amino acid sequence of SEQ ID NO: 222 (H17);   (2) a heavy chain comprising the amino acid sequence of SEQ ID NO: 223 (H19);   (3) a heavy chain comprising the amino acid sequence of SEQ ID NO: 224 (H28);   (4) a heavy chain comprising the amino acid sequence of SEQ ID NO: 225 (H30);   (5) a heavy chain comprising the amino acid sequence of SEQ ID NO: 226 (H34);   (6) a heavy chain comprising the amino acid sequence of SEQ ID NO: 227 (H42);   (7) a heavy chain comprising the amino acid sequence of SEQ ID NO: 228 (H44);   (8) a heavy chain comprising the amino acid sequence of SEQ ID NO: 229 (H46);   (9) a heavy chain comprising the amino acid sequence of SEQ ID NO: 230 (H57);   (10) a heavy chain comprising the amino acid sequence of SEQ ID NO: 231 (H71);   (11) a heavy chain comprising the amino acid sequence of SEQ ID NO: 232 (H78);   (12) a heavy chain comprising the amino acid sequence of SEQ ID NO: 233 (H92);   (13) a heavy chain comprising the amino acid sequence of SEQ ID NO: 234 (H97);   (14) a heavy chain comprising the amino acid sequence of SEQ ID NO: 235 (H98);   (15) a light chain comprising the amino acid sequence of SEQ ID NO: 236 (L11);   (16) a light chain comprising the amino acid sequence of SEQ ID NO: 237 (L12);   (17) a light chain comprising the amino acid sequence of SEQ ID NO: 238 (L17);   (18) a light chain comprising the amino acid sequence of SEQ ID NO: 239 (L50);   (19) an antibody comprising the heavy chain of (3) and the light chain of (17) (H28L17);   (20) an antibody comprising the heavy chain of (4) and the light chain of (17) (H30L17);   (21) an antibody comprising the heavy chain of (5) and the light chain of (17) (H34L17);   (22) an antibody comprising the heavy chain of (6) and the light chain of (17) (H42L17);   (23) an antibody comprising the heavy chain of (7) and the light chain of (17) (H44L17);   (24) an antibody comprising the heavy chain of (8) and the light chain of (17) (H46L17);   (25) an antibody comprising the heavy chain of (9) and the light chain of (17) (H57L17);   (26) an antibody comprising the heavy chain of (10) and the light chain of (17) (H71L17);   (27) an antibody comprising the heavy chain of (11) and the light chain of (17) (H78L17);   (28) an antibody comprising the heavy chain of (12) and the light chain of (17) (H92L17);   (29) an antibody comprising the heavy chain of (13) and the light chain of (18) (H97L50);   (30) an antibody comprising the heavy chain of (14) and the light chain of (18) (H98L50);   (31) an antibody comprising a heavy chain variable region at least 95% identical and a light chain variable region at least 95% identical to the heavy and light chain variable regions of the antibody of any one of (19) to (30); and   (32) an antibody which binds to the same epitope as an epitope bound by the antibody of any one of (19) to (30).   
     
     
         12 . A pharmaceutical composition comprising the antibody of  claim 1 . 
     
     
         13 . (canceled) 
     
     
         14 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 1 . 
     
     
         15 . The anti-NR10 antibody of  claim 5 , which is a humanized antibody. 
     
     
         16 . The anti-NR10 antibody of  claim 6 , which is a humanized antibody. 
     
     
         17 . The anti-NR10 antibody of  claim 7 , which is a humanized antibody. 
     
     
         18 . The anti-NR10 antibody of  claim 8 , which is a humanized antibody. 
     
     
         19 . The anti-NR10 antibody of  claim 9 , which is a humanized antibody. 
     
     
         20 . A pharmaceutical composition comprising the antibody of  claim 4 . 
     
     
         21 . A pharmaceutical composition comprising the antibody of  claim 5 . 
     
     
         22 . A pharmaceutical composition comprising the antibody of  claim 6 . 
     
     
         23 . A pharmaceutical composition comprising the antibody of  claim 7 . 
     
     
         24 . A pharmaceutical composition comprising the antibody of  claim 8 . 
     
     
         25 . A pharmaceutical composition comprising the antibody of  claim 9 . 
     
     
         26 . A pharmaceutical composition comprising the antibody of  claim 10 . 
     
     
         27 . A pharmaceutical composition comprising the antibody of  claim 11 . 
     
     
         28 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 4 . 
     
     
         29 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 5 . 
     
     
         30 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 6 . 
     
     
         31 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 7 . 
     
     
         32 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 8 . 
     
     
         33 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 9 . 
     
     
         34 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 10 . 
     
     
         35 . A method for treating or preventing an inflammatory disease, which comprises the step of administering the antibody of  claim 11 . 
     
     
         36 . A pharmaceutical composition comprising the antibody of  claim 15 . 
     
     
         37 . A pharmaceutical composition comprising the antibody of  claim 16 . 
     
     
         38 . A pharmaceutical composition comprising the antibody of  claim 17 . 
     
     
         39 . A pharmaceutical composition comprising the antibody of  claim 18 . 
     
     
         40 . A pharmaceutical composition comprising the antibody of  claim 19 . 
     
     
         41 . A method for treating or preventing inflammatory diseases, which comprises the step of administering the antibody of  claim 15 . 
     
     
         42 . A method for treating or preventing inflammatory diseases, which comprises the step of administering the antibody of  claim 16 . 
     
     
         43 . A method for treating or preventing inflammatory diseases, which comprises the step of administering the antibody of  claim 17 . 
     
     
         44 . A method for treating or preventing inflammatory diseases, which comprises the step of administering the antibody of  claim 18 . 
     
     
         45 . A method for treating or preventing inflammatory diseases, which comprises the step of administering the antibody of  claim 19 .

Join the waitlist — get patent alerts

Track US2011129459A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.